Neurosense Therapeutics News - October 2026
🟢 Neurosense Therapeutics is trading 19.66% up in pre-market, with no confirmed company-specific catalyst
Neurosense Therapeutics is trading 19.66% up in pre-market at $2.80, with biotech-sector strength reported as supportive context but not a confirmed direct...
🟢 Neurosense Therapeutics is trading 32.48% up in after-hours trading
Neurosense Therapeutics is trading at $3.10, up +32.48% in after-hours trading; no verified company-specific catalyst was identified for October 20, 2026. -...
🔴 Neurosense Therapeutics is trading 13.68% down in after-hours trading
Neurosense Therapeutics is trading at $2.02, down 13.68% in after-hours trading, with no verified company-specific catalyst identified. - On October 20, it...
🔴 Neurosense Therapeutics is trading 13.88% down with no verified company-specific catalyst identified
Neurosense Therapeutics is trading at $2.29, down 13.88%, with no verified company-specific catalyst identified for the October 20 decline. - October 19 news...
🔴 Neurosense Therapeutics is trading 18.3% down in after-hours trading — no specific cause established
Neurosense Therapeutics is trading at $2.85, down 18.34% in after-hours trading; available evidence does not establish a specific cause. - Nasdaq appeal...
NeuroSense Buys Time on Nasdaq, but Can a $13 Million Biotech Close a $35 Million Gap Before the Clock Runs Out?
Shares of NeuroSense Therapeutics surged 13.2% to $3.95 after the company disclosed that a Nasdaq Hearings Panel will review its delisting appeal on November...
🟢 Neurosense Therapeutics is trading 13.2% up in after-hours trading amid Nasdaq appeal update
Neurosense Therapeutics is trading 13.2% up at $3.95 after closing at $3.49 on October 13; the Nasdaq update is a plausible company-specific catalyst, but the...
NeuroSense Fights to Stay on Nasdaq — But Can a Small Biotech Buy Enough Time to Survive?
Shares of NeuroSense Therapeutics surged 15.4% to $4.54 on October 5, snapping a five-session slide, after the company disclosed plans to appeal Nasdaq's move...
🟢 Neurosense Therapeutics is trading 15.4% up today amid plan to appeal Nasdaq compliance determination
Neurosense Therapeutics is trading 15.4% higher at $4.54; its October 2 plan to appeal Nasdaq’s minimum market-value determination is the clearest relevant...